These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23627243)

  • 1. Treatment of canine pulmonary arterial hypertension: is tadalafil an appropriate alternative to sildenafil?
    Wung D
    Int J Pharm Compd; 2013; 17(1):24-7. PubMed ID: 23627243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients.
    Tay EL; Geok-Mui MK; Poh-Hoon MC; Yip J
    Int J Cardiol; 2008 Apr; 125(3):416-7. PubMed ID: 17407795
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.
    Chaumais MC; Perrin S; Sitbon O; Simonneau G; Humbert M; Montani D
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1193-205. PubMed ID: 23944387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
    Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
    Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and validated quantification of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, tadalafil, and 2 of their metabolites in human blood plasma by LC-MS/MS--application to forensic and therapeutic drug monitoring cases.
    Rust KY; Wilkens H; Kaiser R; Bregel D; Wilske J; Kraemer T
    Ther Drug Monit; 2012 Dec; 34(6):729-35. PubMed ID: 23128911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
    Frantz RP; Durst L; Burger CD; Oudiz RJ; Bourge RC; Franco V; Waxman AB; McDevitt S; Walker S
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):550-7. PubMed ID: 24742768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension].
    Sakuma M; Shirato K
    Nihon Rinsho; 2008 Nov; 66(11):2157-61. PubMed ID: 19051736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].
    Kiliçkesmez K; Küçükoğlu MS
    Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():16-8. PubMed ID: 20819751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.
    Sabri MR; Beheshtian E
    Pediatr Cardiol; 2014 Apr; 35(4):699-704. PubMed ID: 24253611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
    Channick R; Preston I; Klinger JR
    Clin Chest Med; 2013 Dec; 34(4):811-24. PubMed ID: 24267306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial experience with tadalafil in pediatric pulmonary arterial hypertension.
    Takatsuki S; Calderbank M; Ivy DD
    Pediatr Cardiol; 2012 Jun; 33(5):683-8. PubMed ID: 22402804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil.
    Levin YD; White RJ
    Drugs Today (Barc); 2011 Feb; 47(2):145-56. PubMed ID: 21431102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and outcome of 13 dogs with pulmonary arterial hypertension (PH) treated with sildenafil.
    Moreno HJ
    J Vet Intern Med; 2007; 21(6):1165. PubMed ID: 18196719
    [No Abstract]   [Full Text] [Related]  

  • 15. Tadalafil for the treatment of pulmonary arterial hypertension.
    Rosenzweig EB
    Expert Opin Pharmacother; 2010 Jan; 11(1):127-32. PubMed ID: 20001434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot study.
    Jaffey JA; Leach SB; Kong LR; Wiggen KE; Bender SB; Reinero CR
    J Vet Cardiol; 2019 Aug; 24():7-19. PubMed ID: 31405557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension.
    Lichtblau M; Harzheim D; Ehlken N; Marra A; Pinado FP; Grünig E; Egenlauf B
    Lung; 2015 Feb; 193(1):105-12. PubMed ID: 25318865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
    Ghofrani HA; Grimminger F
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
    Ali ST
    Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of long-term sildenafil therapy in a young dog with pulmonary hypertension.
    Toyoshima Y; Kanemoto I; Arai S; Toyoshima H
    J Vet Med Sci; 2007 Oct; 69(10):1073-5. PubMed ID: 17984597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.